OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Issue Information	339
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	261
Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients	251
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	216
In this Issue	139
ASCPT News	124
In This Issue	120
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	116
	112
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	110
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	95
FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception	95
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	89
Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies	80
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice	74
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	66
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	63
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	62
Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers	61
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	60
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers	56
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience	55
Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov	52
A Biological Basis for Pharmacokinetics: The Remote Sensing and Signaling Theory	51
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers	49

Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	49
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	49
Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis	46
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	45
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance	44
Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma	44
Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives	44
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination	44
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	43
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	42
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	41
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	41
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	41
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors	39
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	39